FDA to Review 3-Antigen Prophylactic Hepatitis B Vaccine
The vaccine candidate consists of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus.
Treatments
High-Titer Convalescent Plasma Therapy Within 72 Hours of COVID-19 Symptoms Reduced Risk for Severe Illness
Study authors assessed whether convalescent plasma with high SARS-CoV-2 antibody titers would prevent progression to severe disease in older patients with COVID-19 if administered within 72 hours after the onset of mild symptoms.
Umifenovir Contributes to Clinical and Laboratory Improvement of COVID-19 Management
A randomized controlled trial was conducted to evaluate the efficacy of umifenovir as a monotherapy for the hospitalized patients with COVID-19.
Early Data Show Regeneron Cocktail Prevents Symptomatic COVID-19 Infection
REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein.
Comparing Culture-Positive and -Negative Pyogenic Vertebral Osteomyelitis
The goal of this study is to investigate the antimicrobial therapy, therapeutic response, and outcome of culture-negative PVO compared with culture-positive PVO.
WHO: Remdesivir, Hydroxychloroquine, Lopinavir, Interferon Ineffective for COVID-19
World Health Organization expert provided data on 4 repurposed antiviral drugs – remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a – and its use in patients hospitalized with COVID-19.
Regeneron’s Antibody Cocktail Reduces COVID-19 Viral Load in Phase 1/2 Trial
Regeneron’s antibody cocktail for COVID-19, REGN-COV2, contains 2 neutralizing antibodies: casirivimab and imdevimab; results from the phase 1/2 trial reveal promising results for patients who were antibody-negative or had high viral loads.
Valganciclovir and Ganciclovir Effective for HIV-Associated CMVR in Low- and Middle-Income Countries
The study authors describe the first use of valganciclovir treatment in lower-income countries for patients with CMVR, advanced HIV disease, and profound immunosuppression.
Switch From Efavirenz to Integrase Strand Transfer Inhibitors Related to Weight Gain
Researchers studied 61 HIV-infected individuals who switched from efavirenz- to integrase strand transfer inhibitor (INSTI)-based therapies.
Updates and Challenges for WHO Antibiotic Targets
Investigators reviewed patterns of antibiotic consumption in each of the WHO Access, Watch, and Reserve (AWaRe) categories over a span of 15 years and documented changes.
-
Loading...
-
Loading...
Next post in Antibiotics, Antimicrobial Resistance
